Loading…
Design Therapeutics, Inc. is projected to rise to $15.82 by 2027, a +43% move from its current price of $11.10. DSGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.58 | $11.10 | $11.64 | -0.01% |
| May 30 | $10.38 | $11.10 | $11.87 | -0.01% |
| May 31 | $10.22 | $11.10 | $12.05 | -0.02% |
| Jun 1 | $10.09 | $11.10 | $12.21 | -0.02% |
| Jun 2 | $9.98 | $11.10 | $12.34 | -0.03% |
| Jun 3 | $9.87 | $11.10 | $12.47 | -0.04% |
| Jun 4 | $9.78 | $11.10 | $12.59 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.78 | $11.10 | $12.59 | -0.04% |
| Week 2 | $9.28 | $11.09 | $13.25 | -0.09% |
| Week 3 | $8.91 | $11.09 | $13.79 | -0.13% |
| Week 4 | $8.61 | $11.08 | $14.26 | -0.17% |
| Week 5 | $8.36 | $11.08 | $14.68 | -0.22% |
| Week 6 | $8.13 | $11.07 | $15.08 | -0.26% |
| Week 7 | $7.93 | $11.07 | $15.45 | -0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company that researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprise Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
The company was incorporated in 2017 and is headquartered in Carlsbad, California.
DSGN trades as a healthcare stock with a current price of $10.97 and a market capitalization of $685.15M. It is ranked 2802 by market cap.
The forecast presents an upward price trajectory across years, with the 2026 avg price at $10.97 (NEUTRAL) and higher averages thereafter, reaching $33.91 by 2030 and $296.12 by 2050. The forecast also shows higher max values in later years, such as $57.79 in 2030, $188.68 in 2040, and $681.07 in 2050, indicating substantial upside potential over the period.
A major floor 35.5% below — a decisive break under it would weaken the trend.
The nearest floor, 5.5% below — buyers have tended to step in here.
The nearest ceiling, 42.3% above — a clean break opens room to run.
A major ceiling 60.0% above — clearing it would confirm fresh momentum.
Key DSGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DSGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.12 | Sell | $11.31 | Sell |
| MA 10 | $12.13 | Sell | $11.91 | Sell |
| MA 20 | $13.24 | Sell | $12.49 | Sell |
| MA 50 | $12.37 | Sell | $12.29 | Sell |
| MA 100 | $11.20 | Sell | $11.29 | Sell |
| MA 200 | $9.15 | Buy | $9.64 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.38 | Neutral |
| Stoch RSI (14) | 15.63 | Buy |
| CCI (20) | -89.27 | Neutral |
| Williams %R (14) | -88.49 | Info |
| MACD (12,26,9) | -0.43 | Sell |
| ROC (12) | -21.94 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 11.51 | Buy |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | -1.93 | Sell |
| Ultimate (7,14,28) | 26.44 | Buy |
| Momentum (10) | -4.69 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 10.83 | Buy |
| ADX (14) | 22.41 | Sell |
| ATR (14) | 0.59 | Info |
The short-term picture shows a BULLISH sentiment with an RSI(14) of 40.
The 50-day simple moving average is $12.35 and the 200-day simple moving average is $9.08, with near-term support at $10.49 and resistance at $15.79. The 30-day trading range is $7.90 to $15.23, illustrating the recent volatility boundaries investors are watching.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.69 | $11.10 | $17.61 | 0% | Neutral | |
| $11.64 | $15.82 | $23.20 | +43% | Bullish | |
| $14.45 | $20.68 | $32.08 | +86% | Bullish | |
| $20.72 | $30.99 | $50.22 | +179% | Bullish | |
| $22.66 | $35.28 | $59.30 | +218% | Bullish | |
| $23.21 | $37.51 | $65.06 | +238% | Bullish | |
| $24.31 | $40.72 | $72.62 | +267% | Bullish | |
| $24.55 | $42.53 | $77.80 | +283% | Bullish | |
| $30.82 | $55.19 | $103.30 | +397% | Bullish | |
| $39.41 | $72.85 | $139.29 | +556% | Bullish | |
| $44.91 | $96.74 | $201.96 | +772% | Bullish | |
| $143.99 | $319.97 | $735.93 | +27.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.69 | $11.10 | $13.25 | +0.00% |
| June 2026 | $9.62 | $11.49 | $14.17 | +3.47% |
| July 2026 | $9.11 | $11.04 | $13.93 | -3.90% |
| August 2026 | $9.23 | $11.32 | $14.54 | +2.54% |
| September 2026 | $9.93 | $12.29 | $16.00 | +8.57% |
| October 2026 | $10.00 | $12.49 | $16.47 | +1.62% |
| November 2026 | $9.80 | $12.34 | $16.46 | -1.16% |
| December 2026 | $10.30 | $13.07 | $17.61 | +5.88% |
Click any year to see its month-by-month DSGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DSGN to range from $8.69 to $17.61 through 2026. The $11.10 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DSGN price prediction for 2027 points to an average of $15.82 (low $11.64, high $23.20) — a potential gain of +43% on today's $11.10. Momentum favours further upside here.
In 2028, DSGN is projected to trade between $14.45 and $32.08, averaging $20.68 — a potential gain of +86% from today's $11.10. That is up +31% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Design Therapeutics, Inc.'s 2029 outlook centres on $30.99, within a $20.72 to $50.22 range. That is up +50% on the projected 2028 average. That marks a +179% change versus current levels. Momentum favours further upside here.
By 2030, DSGN could reach as high as $59.30, with a base case around $35.28 and support toward $22.66 — roughly +218% from $11.10. Buyers look set to stay in control over this stretch.
Expect DSGN to range from $23.21 to $65.06 through 2031. The $37.51 average target implies a +238% move from current prices. That is up +6% on the projected 2030 average. Momentum favours further upside here.
The DSGN price prediction for 2032 points to an average of $40.72 (low $24.31, high $72.62) — a potential gain of +267% on today's $11.10. Buyers look set to stay in control over this stretch.
In 2033, DSGN is projected to trade between $24.55 and $77.80, averaging $42.53 — a potential gain of +283% from today's $11.10. That is up +4% on the projected 2032 average. Momentum favours further upside here.
Design Therapeutics, Inc.'s 2034 outlook centres on $55.19, within a $30.82 to $103.30 range. That is up +30% on the projected 2033 average. That marks a +397% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DSGN could reach as high as $139.29, with a base case around $72.85 and support toward $39.41 — roughly +556% from $11.10. Momentum favours further upside here.
Expect DSGN to range from $44.91 to $201.96 through 2040. The $96.74 average target implies a +772% move from current prices. That is up +33% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DSGN price prediction for 2050 points to an average of $319.97 (low $143.99, high $735.93) — a potential gain of +27.8x on today's $11.10. Momentum favours further upside here.
Investing $1,000 in DSGN today (≈ 90.09009 DSGN) could be worth
$28,826.09
+$27,826.09 (+2783%) by 2050 · US Dollar
Based on the average projected DSGN price of $319.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DSGNwould be worth at today's price.
$1,000 invested in DSGN on May 27, 2025 (≈ 257.731951 DSGN) would be worth
$2,860.82
+$1,860.82 (+186.1%) today · 2.86× · US Dollar
Based on a DSGN entry price of $3.88 vs. today's $11.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.1 | $1,000 | -0.0% |
| 1 month ago | $12.81 | $866.51 | -13.3% |
| 3 months ago | $10.68 | $1,039.33 | +3.9% |
| 6 months ago | $9.39 | $1,182.11 | +18.2% |
| 1 year ago | $3.88 | $2,860.82 | +186.1% |
| All time (5.0y) ago | $26.12 | $424.96 | -57.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DSGN forecast.
Our base-case forecast reaches $22.00 around 2029.
Implied market cap at $22.00: $1.37B
The multi-year forecast projects continued upside with rising averages and sizable ROI across the horizon.
In 2027 the avg is $15.25 with ROI 39 and a BULLISH sentiment, followed by 2028 with avg $19.85 and ROI 80.9 and a BULLISH stance, then 2029 with avg $30.41 and ROI 177.2 and a BULLISH stance. By 2030, the avg is $33.91 with ROI 209.2 and a BULLISH stance, progressing to 2031 avg $35.58 ROI 224.4 and 2032 avg $39.01 ROI 255.6, 2033 avg $39.65 ROI 261.5, 2034 avg $51.44 ROI 368.9, and 2035 avg $68.79 ROI 527, all marked as BULLISH.
Looking further out, the forecast shows 2040 avg $88.64 ROI 708 and 2050 avg $296.12 ROI 2599.4 with bullish sentiment. These figures illustrate a path of rising average prices and upside potential, though they are estimates and not guarantees.
Tap a question to reveal the answer.
2030 min $21.43, avg $33.91, max $57.79, ROI 209.2, sentiment BULLISH.
The 2026 forecast is min $8.69, avg $10.97, max $17.64, ROI 0, sentiment NEUTRAL; from 2027 onward, the avg rises to $15.25 (ROI 39) and continues higher through 2050 with avg $296.12 and ROI 2599.4, all with a BULLISH sentiment in later years. These are estimates, not guarantees.
Yes. The forecast shows max values exceeding $100 in several years, including 2035 with max $133.83 and 2040 with max $188.68, and 2050 with max $681.07.
Current price: $10.97; Market cap: $685.15M. The asset is ranked 2802.
Avg $15.25; Min $11.12; Max $22.60; ROI 39; Sentiment BULLISH.
Design Therapeutics, Inc. Community Discussion
0Share your Design Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.